1. Klos, A. et al. The role of the anaphylatoxins in health and disease. Mol. Immunol. 46, 2753–2766 (2009).

2. Klos, A., Wende, E., Wareham, K. J. & Monk, P. N. International union of basic and clinical pharmacology. [corrected]. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol. Rev. 65, 500–543 (2013).

3. Bjarnadóttir, T. K. et al. Comprehensive repertoire and phylogenetic analysis of the G protein-coupled receptors in human and mouse. Genomics 88, 263–273 (2006).

4. Guo, R. F. & Ward, P. A. Role of C5a in inflammatory responses. Annu. Rev. Immunol. 23, 821–852 (2005).

5. Fonseca, M. I. et al. Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer’s disease. J. Neuroinflammation 8, 4 (2011).

6. Landlinger, C. et al. Active immunization against complement factor C5a: a new therapeutic approach for Alzheimer’s disease. J. Neuroinflammation 12, 150 (2015).

7. Quadros, A. U. & Cunha, T. M. C5a and pain development: An old molecule, a new target. Pharmacol. Res. 112, 58–67 (2016).

8. Pandey, M. K. et al. Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease. Nature 543, 108–112 (2017).

9. Markiewski, M. M. et al. Modulation of the antitumor immune response by complement. Nat. Immunol. 9, 1225–1235 (2008).

10. Nitta, H. et al. Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88). Clin. Cancer Res. 19, 2004–2013 (2013).

11. Vadrevu, S. K. et al. Complement c5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche. Cancer Res. 74, 3454–3465 (2014).

12. Darling, V. R., Hauke, R. J., Tarantolo, S. & Agrawal, D. K. Immunological effects and therapeutic role of C5a in cancer. Expert Rev. Clin. Immunol. 11, 255–263 (2015).

13. Woodruff, T. M., Nandakumar, K. S. & Tedesco, F. Inhibiting the C5-C5a receptor axis. Mol. Immunol. 48, 1631–1642 (2011).

14. Finch, A. M. et al. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J. Med. Chem. 42, 1965–1974 (1999).

15. March, D. R. et al. Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity. Mol. Pharmacol. 65, 868–879 (2004).

16. Monk, P. N., Scola, A. M., Madala, P. & Fairlie, D. P. Function, structure and therapeutic potential of complement C5a receptors. Br. J. Pharmacol. 152, 429–448 (2007).

17. Sumichika, H. et al. Identification of a potent and orally active non-peptide C5a receptor antagonist. J. Biol. Chem. 277, 49403–49407 (2002).

18. Brodbeck, R. M. et al. Identification and characterization of NDT 9513727 [N,N-bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1H-imidazole-5-methanamine], a novel, orally bioavailable C5a receptor inverse agonist. J. Pharmacol. Exp. Ther. 327, 898–909 (2008).

19. Bekker, P. et al. Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized phase 1 clinical study. PLoS One 11, e0164646 (2016).

20. Seow, V. et al. Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists. Sci. Rep. 6, 24575 (2016).

21. Jayne, D. R. W. et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J. Am. Soc. Nephrol. 28, 2756–2767 (2017).

22. Robertson, N. et al. Structure of the complement C5a receptor bound to the extra-helical antagonist NDT9513727. Nature 553, 111–114 (2018).

23. Lu, J. et al. Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40. Nat. Struct. Mol. Biol. 24, 570–577 (2017).

24. Chun, E. et al. Fusion partner toolchest for the stabilization and crystallization of G protein-coupled receptors. Structure 20, 967–976 (2012).

25. Finch, A. M. et al. Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity. J. Med. Chem. 40, 877–884 (1997).

26. Siciliano, S. J. et al. Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors. Proc. Natl. Acad. Sci. USA 91, 1214–1218 (1994).

27. Klco, J. M., Lassere, T. B. & Baranski, T. J. C5a receptor oligomerization. I. Disulfide trapping reveals oligomers and potential contact surfaces in a G protein-coupled receptor. J. Biol. Chem. 278, 35345–35353 (2003).

28. White, J. F. et al. Structure of the agonist-bound neurotensin receptor. Nature 490, 508–513 (2012).

29. Qin, L. et al. Structural biology. Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine. Science 347, 1117–1122 (2015).

30. Shihoya, W. et al. Activation mechanism of endothelin ET B receptor by endothelin-1. Nature 537, 363–368 (2016).

31. Ma, Y. et al. Structural basis for apelin control of the human apelin receptor. Structure 25, 858–866.e854 (2017).

32. Cain, S. A., Coughlan, T. & Monk, P. N. Mapping the ligand-binding site on the C5a receptor: arginine74 of C5a contacts aspartate282 of the C5a receptor. Biochemistry 40, 14047–14052 (2001).

33. Baranski, T. J. et al. C5a receptor activation. Genetic identification of critical residues in four transmembrane helices. J. Biol. Chem. 274, 15757–15765 (1999).

34. Higginbottom, A. et al. Comparative agonist/antagonist responses in mutant human C5a receptors define the ligand binding site. J. Biol. Chem. 280, 17831–17840 (2005).

35. Nikiforovich, G. V., Marshall, G. R. & Baranski, T. J. Modeling molecular mechanisms of binding of the anaphylatoxin C5a to the C5a receptor. Biochemistry 47, 3117–3130 (2008).

36. Qu, H., Ricklin, D. & Lambris, J. D. Recent developments in low molecular weight complement inhibitors. Mol. Immunol. 47, 185–195 (2009).

37. Waters, S. M. et al. Molecular characterization of the gerbil C5a receptor and identification of a transmembrane domain V amino acid that is crucial for small molecule antagonist interaction. J. Biol. Chem. 280, 40617–40623 (2005).

38. Zhang, D. et al. Two disparate ligand-binding sites in the human P2Y1 receptor. Nature 520, 317–321 (2015).

39. Gerber, B. O., Meng, E. C., Dotsch, V., Baranski, T. J. & Bourne, H. R. An activation switch in the ligand binding pocket of the C5a receptor. J. Biol. Chem. 276, 3394–3400 (2001).

40. Wu, B. et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330, 1066–1071 (2010).

41. Konteatis, Z. D. et al. Development of C5a receptor antagonists. Differential loss of functional responses. J. Immunol. 153, 4200–4205 (1994).

42. Jia, N. et al. Pivotal advance: Interconversion between pure chemotactic ligands and chemoattractant/secretagogue ligands of neutrophil C5a receptor by a single amino acid substitution. J. Leukoc. Biol. 87, 965–975 (2010).

43. Rasmussen, S. G. et al. Structure of a nanobody-stabilized active state of the β(2) adrenoceptor. Nature 469, 175–180 (2011).

44. Huang, W. et al. Structural insights into µ-opioid receptor activation. Nature 524, 315–321 (2015).

45. Whistler, J. L. et al. Constitutive activation and endocytosis of the complement factor 5a receptor: evidence for multiple activated conformations of a G protein-coupled receptor. Traffic 3, 866–877 (2002).

46. Angel, T. E., Chance, M. R. & Palczewski, K. Conserved waters mediate structural and functional activation of family A (rhodopsin-like) G protein-coupled receptors. Proc. Natl. Acad. Sci. USA 106, 8555–8560 (2009).

47. Fenalti, G. et al. Molecular control of δ-opioid receptor signalling. Nature 506, 191–196 (2014).

48. Liu, W. et al. Structural basis for allosteric regulation of GPCRs by sodium ions. Science 337, 232–236 (2012).

49. Zhang, C. et al. High-resolution crystal structure of human protease-activated receptor 1. Nature 492, 387–392 (2012).

50. Li, S., Lee, S. Y. & Chung, K. Y. Conformational analysis of g protein-coupled receptor signaling by hydrogen/deuterium exchange mass spectrometry. Methods Enzymol 557, 261–278 (2015).

51. Konermann, L., Tong, X. & Pan, Y. Protein structure and dynamics studied by mass spectrometry: H/D exchange, hydroxyl radical labeling, and related approaches. J. Mass Spectrom. 43, 1021–1036 (2008).

52. Suvorova, E. S., Gripentrog, J. M., Oppermann, M. & Miettinen, H. M. Role of the carboxyl terminal di-leucine in phosphorylation and internalization of C5a receptor. Biochim. Biophys. Acta 1783, 1261–1270 (2008).

53. Rasmussen, S. G. et al. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 477, 549–555 (2011).

54. Zhou, X. E. et al. Identification of phosphorylation codes for arrestin recruitment by G protein-coupled receptors. Cell 170, 457–469.e413 (2017).

55. Gripentrog, J. M. & Miettinen, H. M. Formyl peptide receptor-mediated ERK1/2 activation occurs through G(i) and is not dependent on beta-arrestin1/2. Cell. Signal. 20, 424–431 (2008).

56. Moriconi, A. et al. Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief. Proc. Natl. Acad. Sci. USA 111, 16937–16942 (2014).

57. Zeng, Q. et al. Discovery of an irreversible HCV NS5B polymerase inhibitor. Bioorg. Med. Chem. Lett. 23, 6585–6587 (2013).

58. Li, R., Coulthard, L. G., Wu, M. C., Taylor, S. M. & Woodruff, T. M. C5L2: a controversial receptor of complement anaphylatoxin, C5a. FASEB J. 27, 855–864 (2013).

59. Van Lith, L. H., Oosterom, J., Van Elsas, A. & Zaman, G. J. C5a-stimulated recruitment of beta-arrestin2 to the nonsignaling 7-transmembrane decoy receptor C5L2. J. Biomol. Screen. 14, 1067–1075 (2009).

60. Zhang, H. et al. Structural basis for selectivity and diversity in angiotensin II receptors. Nature 544, 327–332 (2017).

61. Caffrey, M. Crystallizing membrane proteins for structure determination: use of lipidic mesophases. Annu. Rev. Biophys. 38, 29–51 (2009).

62. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307–326 (1997).

63. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007).

64. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221 (2010).

65. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132 (2004).

66. Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12–21 (2010).

67. Williams, C. J. et al. MolProbity: More and better reference data for improved all-atom structure validation. Protein Sci. 27, 293–315 (2018).

68. Mysinger, M. M. & Shoichet, B. K. Rapid context-dependent ligand desolvation in molecular docking. J. Chem. Inf. Model. 50, 1561–1573 (2010).